NCT03981614View on ClinicalTrials.gov

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

August 23, 2021

Study Completion Date

July 2, 2024

Conditions
Metastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Unresectable Carcinoma
Interventions
DRUG

Binimetinib

Given PO

DRUG

Palbociclib

Given PO

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Trial Locations (7)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

37232

Vanderbilt University/Ingram Cancer Center, Nashville

67214

Cancer Center of Kansas - Wichita, Wichita

77030

M D Anderson Cancer Center, Houston

85259

Mayo Clinic in Arizona, Scottsdale

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Academic and Community Cancer Research United

OTHER

NCT03981614 - Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | Biotech Hunter | Biotech Hunter